Outcomes of Fludarabine, High Dose Cytarabine and Granulocyte-Colony Stimulating Factor (FLAG) as Re-induction for Residual Acute Myeloid Leukemia on Day 14 Bone Marrow
Acute myeloid leukemia (AML) is primarily a disease of the elderly with the median age at diagnosis being 68 years and nearly 20,000 new cases are diagnosed annually in the United States [1,2]. Patients diagnosed with non-M3 AML fit to receive intensive chemotherapy are treated with induction therapy consisting of an anthracycline and cytarabine [2 –4]. Prognosis of AML is affected by karyotype and molecular aberrations with the majority of patients remaining at risk of relapse. Hematopoietic stem cell transplantation (HSCT) is recommended for patients with adverse prognostic features.
Source: Leukemia Research - Category: Hematology Authors: Omer Jamy, Sejong Bae, Luciano J. Costa, Harry P. Erba, Nikolaos Papadantonakis Tags: Research paper Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Chemotherapy | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants | USA Health